IFPMA International Federation of Pharmaceutical Manufacturers & Associations

GLG Barbados Meeting

James Anderson, Executive Director of Global Health at IFPMA, and AMR Industry Alliance Chair

The industry is committed to addressing AMR



IFPMA

Why we need action

Antibiotic Pipeline is weak….and mortality is high

A.3. Products by pathogen category and phase

Pathogen category	Phase I	Phase II	Phase III	Preregist..	Total
Priority pathogens	16	3	8	1	28
Mycobacterium tuberculosis	6	7			13
Clostridioides difficile		4	1		5
Total	22	14	9	1	46

C.1. Innovative?





C.1. Innovative? Phase 3 only

N=46

*Source: Pipeline of antibacterial products in clinical development (who.int); AMR clinical pipeline_June2022 | Tableau Public

IFPMA

Bridging the AMR R&D clinical funding gap

2020

2022

In April 2022, the AMR Action Fund announced its first two investments.

Venatorx PHARMACEUTICALS

adaptive phage THERAPEUTICS

2023

In January 2023, the AMR Action Fund announced its third investment.

BIOVERSYS

Responding to the clinical AMR R&D funding gap, a bridging **$1 billion AMR Action Fund** is established in partnership with WHO, Wellcome Trust, and the European Investment Bank. Over 20 large IFPMA member pharmaceutical companies invested, and funding was also provided by the European Investment Bank and the Wellcome Trust.

AMR Action Fund: https://amractionfund.com/

IFPMA

The life-sciences industry is also working to holistically address the challenges of AMR

Established 2017

amr INDUSTRY ALLIANCE

research & science

appropriate use

access

manufacturing

In 2022, the AMR Alliance released its 3rd Progress Report, showcasing progress of the life-sciences industry across its focus areas.

In FY 2019 and 2020, Alliance member companies **invested between 1.8 and 1.9 billion USD into AMR R&D** – but these investment levels are threatened.

Four out of five (81%) surveyed companies reported being active in supporting access to AMR-relevant products and/or technologies. Implementation of appropriate use and stewardship activities were also reported as a major focus of companies, with 92% of R&D pharmaceutical companies, 89% of generics companies, and 80% of diagnostics companies having taken such actions.

AMR Industry Alliance: https://www.amrindustryalliance.org/progress-report/

IFPMA

Alliance progress in 2022

- The Alliance published its **Antibiotic Manufacturing Standard**, which provides clear guidance to manufacturers in the global antibiotic supply chain to ensure that their antibiotics are made responsibly.

- The Alliance **commissioned a report on the sustainability of the off-patent supply chain** to gain insight into the root causes of supply chain instability among off-patent antimicrobials and identify potential policy solutions to address these issues. The report will be published in February 2023.

- The Alliance commissioned a report by the One Health Trust on drug regulatory approvals and opportunities for antimicrobial innovation, describing the current climate for antimicrobial innovation, focusing on regulatory pathways, and **providing recommendations to accelerate the approval of antibiotics in emerging markets (Brazil, India, and South Africa as case studies)**.

- The Alliance **awarded its second annual stewardship prize to Lekma Hospital in Ghana and the Clinical Engagement Program in Pakistan, led by DAI**. The yearly Stewardship Prize acknowledges organizations' innovative approaches to AMR stewardship in their communities, with the goal of highlighting best practices and inspiring examples.

Alliance ambition in 2023

- Alliance members have shown their willingness to self-regulate by developing the AMRIA Manufacturing Standard and are **working with British Standards Institution (BSI) to develop an independent certification scheme**. In addition, the Alliance **will continue to work to drive widespread adoption of the Standard across the industry** to significantly reduce AMR risk from antibiotic manufacturing, contributing to the overall reduction of environmental AMR risk.

- **BD, BioMerieux, Pfizer, and the Alliance supported a Wellcome Trust project that assessed diagnostics' effectiveness in improving antimicrobial stewardship programs**. The research team recently submitted a preliminary summary of the findings to ECCMID.

- The Alliance is working on a whitepaper on the role of diagnostics in NAPs. **The whitepaper will highlight the necessity to include diagnostics in NAPs** and increase awareness of diagnostics' important role in stewardship and appropriate use.

- The Alliance is working on a report on the human resources shortage in the field of antimicrobial R&D, aiming to **evaluate the current state of the antimicrobial researcher workforce and consider ways to ensure its sustainability moving forward.**

IFPMA

Thank you

/company/ifpma

@ifpma